|
|
Advances in Production of Monoclonal Antibody and Antibody Fragments in Engineered Prokaryotes and Yeast |
ZHAO Yan-shu,ZHANG Jin-hua,SONG Hao() |
Key Laboratory of Systems Bioengineering of Ministry of Education, School of Chemical Engineering amd Technology,Tianjin University, Tianjin 300072, China |
|
|
Abstract Monoclonal antibodies and antibody fragments play important roles in the pharmaceutical market. They are mainly produced in mammalian cell systems, which have several limitations such as complex manipulation and high costs. For purpose of using cheap drugs, monoclonal antibodies and antibody fragments have been produced in prokaryotes and yeasts. However, the lack of glycosylation and the low yield of antibodies prevent their development. The progress has been made recently in the prokaryotes and yeasts to enhance the antibodies production via optimization of transcription and translation, co-expressing chaperones and inhibiting proteolytic degradation, etc. This will lay the foundation for the industrialization production of antibodies in prokaryotes and yeasts.
|
Received: 02 April 2020
Published: 10 September 2020
|
|
Corresponding Authors:
Hao SONG
E-mail: hsong@tju.edu.cn
|
|
|
[1] |
Liu J K. The history of monoclonal antibody development-progress, remaining challenges and future innovations. Annals of Medicine and Surgery, 2014,3(4):113-116.
doi: 10.1016/j.amsu.2014.09.001
pmid: 25568796
|
|
|
[2] |
汪艳艳, 毛晓燕. 重组单克隆抗体药物的工程细胞培养工艺研究. 微生物学免疫学进展, 2019(5):23.
|
|
|
[2] |
Wang Y Y, Mao X Y. Research on engineering cell culture technology of recombinant monoclonal antibody drugs. Advances in Microbiology and Immunology, 2019 ( 5):23.
|
|
|
[3] |
Ambrogelly A, Gozo S, Katiyar A, et al. Analytical comparability study of recombinant monoclonal antibody therapeutics. MAbs, 2018,10(4):513-538.
doi: 10.1080/19420862.2018.1438797
pmid: 29513619
|
|
|
[4] |
Chen C, Snedecor B, Nishihara J C, et al. High-level accumulation of a recombinant antibody fragment in the periplasm of Escherichia coli requires a triple-mutant (degP prc spr) host strain. Biotechnol Bioeng, 2004,85(5):463-474.
doi: 10.1002/bit.20014
pmid: 14760686
|
|
|
[5] |
Ristov J, Espie P, Ulrich P, et al. Characterization of the in vitro and in vivo properties of CFZ533, ablocking and non-depleting anti-CD40 monoclonal antibody. American Journal of Transplantation, 2018,18(1).
pmid: 28801953
|
|
|
[6] |
Bouattour M, Raymond E, Qin S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology, 2018,67(3):1132-1149.
doi: 10.1002/hep.29496
pmid: 28862760
|
|
|
[7] |
Singh R P, Kaiser P K. Role of ranibizumab in management of macular degeneration. Indian J Ophthalmol, 2007,55(6):421-425.
doi: 10.4103/0301-4738.36475
pmid: 17951897
|
|
|
[8] |
Goel N, Stephens S. Certolizumab pegol. Mabs, 2012,2(2):137-147.
doi: 10.4161/mabs.2.2.11271
pmid: 20190560
|
|
|
[9] |
Spiess C, Merchant M, Huang A, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nature Biotechnology, 2013,31(8):753-758.
doi: 10.1038/nbt.2621
pmid: 23831709
|
|
|
[10] |
Mamat U, Wilke K, Bramhill D, et al. Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. Microbial Cell Factories, 2015,14(1):57-57.
doi: 10.1186/s12934-015-0241-5
|
|
|
[11] |
Lee Y J, Lee D H, Jeong K J. Enhanced production of human full-length immunoglobulin G1 in the periplasm of Escherichia coli. Appl Microbiol Biotechnol, 2014,98(3):1237-1246.
doi: 10.1007/s00253-013-5390-z
pmid: 24270917
|
|
|
[12] |
Kellner C, Derer S, Valerius T, et al. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods, 2014,65(1):105-113.
doi: 10.1016/j.ymeth.2013.06.036
|
|
|
[13] |
Lee Y J, Lee D H, Jeong K J. Enhanced production of human full-length immunoglobulin G1 in the periplasm of Escherichia coli. Applied Microbiology and Biotechnology, 2014,98(3):1237-1246.
doi: 10.1007/s00253-013-5390-z
|
|
|
[14] |
Nelson A L, Reichert J M. Development trends for therapeutic antibody fragments. Nature Biotechnology, 2009,27(4):331-337.
doi: 10.1038/nbt0409-331
pmid: 19352366
|
|
|
[15] |
Yim S S, An S J, Choi J W, et al. High-level secretory production of recombinant single-chain variable fragment (scFv) in Corynebacterium glutamicum. Applied Microbiology and Biotechnology, 2014,98(1):273-284.
doi: 10.1007/s00253-013-5315-x
|
|
|
[16] |
Yousefi M, Farajnia S, Mokhtarzadeh A, et al. Soluble expression of humanized anti-CD20 single chain antibody in Escherichia coli by cytoplasmic chaperones co-expression. Avicenna Journal of Medical Biotechnology, 2017,10(3):141-146.
pmid: 30090206
|
|
|
[17] |
Bird R, Hardman K, Jacobson J, et al. Single-chain antigen-binding proteins. Science, 1988,242(4877):423-426.
doi: 10.1126/science.3140379
pmid: 3140379
|
|
|
[18] |
Better M, Chang C, Robinson R, et al. Escherichia coli secretion of an active chimeric antibody fragment. Science, 1988,240(4855):1041-1043.
doi: 10.1126/science.3285471
pmid: 3285471
|
|
|
[19] |
Goyal M, Chaudhuri T K. GroEL-GroES assisted folding of multiple recombinant proteins simultaneously over-expressed in Escherichia coli. The International Journal of Biochemistry & Cell Biology, 2015,64:277-286.
doi: 10.1016/j.biocel.2015.04.018
pmid: 25957916
|
|
|
[20] |
Shadi A M, Sarrafzadeh M-H, Barar J, et al. Cost-effective batch production process of scFv antibody in Escherichia coli. Human Antibodies, 2018: 1-9.
pmid: 10331181
|
|
|
[21] |
Kasli I M, Thomas O R T, Overton T W. Use of a design of experiments approach to optimise production of a recombinant antibody fragment in the periplasm of Escherichia coli: selection of signal peptide and optimal growth conditions. AMB Express, 2019,9(1).
doi: 10.1186/s13568-019-0920-4
pmid: 31797067
|
|
|
[22] |
Kim S J, Ha G S, Lee G, et al. Enhanced expression of soluble antibody fragments by low-temperature and overdosing with a nitrogen source. Enzyme Microb Technol, 2018,115:9-15.
doi: 10.1016/j.enzmictec.2018.04.002
pmid: 29859607
|
|
|
[23] |
Martineau P, Jones P, Winter G. Expression of an antibody fragment at high levels in the bacterial cytoplasm. Journal of Molecular Biology, 1988,280(1):0-127.
|
|
|
[24] |
Luo M, Zhao M, Cagliero C, et al. A general platform for efficient extracellular expression and purification of Fab from Escherichia coli. Appl Microbiol Biotechnol, 2019,103(8):3341-3353.
doi: 10.1007/s00253-019-09745-8
pmid: 30887174
|
|
|
[25] |
朱继莹, 李运程, 宋春雨, 等. 抗 TNFα 抗体 Fab 片段在大肠杆菌内表达的优化. 生物技术, 2018,28(5):428-433.
|
|
|
[25] |
Zhu J Y, Li Y C, Song C Y, et al. Optimization of expression of anti-TNFα antibody Fab fragments in E. coli. Biotechnology, 2018,28(5):428-433.
|
|
|
[26] |
Corisdeo S, Wang B. Functional expression and display of an antibody Fab fragment in Escherichia coli: study of vector designs and culture conditions. Protein Expression and Purification, 2004,34(2):0-279.
|
|
|
[27] |
Ellis M, Humphreys D P. Bacterial host strain expressing recombinant DSBC: Google Patents, 2017.
|
|
|
[28] |
Ellis M, Patel P, Edon M, et al. Development of a high yielding E. coli periplasmic expression system for the production of humanized Fab’ fragments. Biotechnology Progress, 2017,33(1).
doi: 10.1002/btpr.2372
pmid: 27689785
|
|
|
[29] |
Striedner G, Pfaffenzeller I, Markus L, et al. Plasmid-free T7-based Escherichia coli expression systems. Biotechnol Bioeng, 2010,105(4):786-794.
doi: 10.1002/bit.22598
pmid: 19891007
|
|
|
[30] |
Fink M, Vazulka S, Egger E, et al. Microbioreactor cultivations of fab-producing Escherichia coli reveal genome-integrated systems as suitable for prospective studies on direct Fab expression effects. Biotechnol J, 2019,14(11):e1800637.
doi: 10.1002/biot.201800637
pmid: 31231932
|
|
|
[31] |
Matsuda T, Ito T, Takemoto C, et al. Cell-free synthesis of functional antibody fragments to provide a structural basis for antibody-antigen interaction. PLoS One, 2018,13(2).
doi: 10.1371/journal.pone.0193213
pmid: 29489901
|
|
|
[32] |
Simmons L C, Reilly D, Klimowski L, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. Journal of Immunological Methods, 2002,263(1-2):133-147.
doi: 10.1016/s0022-1759(02)00036-4
pmid: 12009210
|
|
|
[33] |
Makino T, Skretas G, Kang T H, et al. Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies. Metab Eng, 2011,13(2):241-251.
doi: 10.1016/j.ymben.2010.11.002
|
|
|
[34] |
De Boer H A, Comstock L J, Vasser M. The tac promoter: a functional hybrid derived from the trp and lac promoters. Proceedings of the National Academy of Sciences of the United States of America, 1983,80(1):21-25.
|
|
|
[35] |
Zhou Y, Liu P, Gan Y, et al. Enhancing full-length antibody production by signal peptide engineering. Microbial Cell Factories, 2016,15(1):47.
doi: 10.1186/s12934-016-0445-3
|
|
|
[36] |
Yong J L, Dong H L, Jeong K J. Enhanced production of human full-length immunoglobulin G1 in the periplasm of Escherichia coli. Applied Microbiology and Biotechnology, 2014,98(3):1237-1246.
doi: 10.1007/s00253-013-5390-z
|
|
|
[37] |
Mckenna R, Lombana T N, Yamada M, et al. Engineered sigma factors increase full-length antibody expression in Escherichia coli. Metab Eng, 2019,52:315-323.
doi: 10.1016/j.ymben.2018.12.009
pmid: 30610917
|
|
|
[38] |
Zhang J, Zhao Y, Cao Y, et al. Synthetic sRNA-based engineering of Escherichia coli for enhanced production of full-length immunoglobulin G. Biotechnology Journal, 2020: 1900363.
|
|
|
[39] |
Wacker M, Linton D, Hitchen P G, et al. N-Linked glycosylation in campylobacter jejuni and Its functional transfer into E. coli. Science, 2002,298(5599):1790-1793.
doi: 10.1126/science.298.5599.1790
pmid: 12459590
|
|
|
[40] |
Jung S T, Reddy S T, Kang T H, et al. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A, 2010,107(2):604-609.
doi: 10.1073/pnas.0908590107
pmid: 20080725
|
|
|
[41] |
Valderrama-Rincon J D, Fisher A C, Merritt J H, et al. An engineered eukaryotic protein glycosylation pathway in Escherichia coli. Nature Chemical Biology, 2012,8(5):434-436.
doi: 10.1038/NCHEMBIO.921
|
|
|
[42] |
Kightlinger W, Lin L, Rosztoczy M, et al. Design of glycosylation sites by rapid synthesis and analysis of glycosyltransferases. Nature Chemical Biology, 2018,14(6):627-635.
doi: 10.1038/s41589-018-0051-2
pmid: 29736039
|
|
|
[43] |
Lakowitz A, Krull R, Biedendieck R. Recombinant production of the antibody fragment D1.3 scFv with different Bacillus strains. Microbial Cell Factories, 2017,16(1):14.
doi: 10.1186/s12934-017-0625-9
pmid: 28115011
|
|
|
[44] |
David F, Westphal R, Bunk B, et al. Optimization of antibody fragment production in Bacillus megaterium: the role of metal ions on protein secretion. Journal of Biotechnology, 2010,150(1):115-124.
doi: 10.1016/j.jbiotec.2010.07.023
pmid: 20670661
|
|
|
[45] |
Mizukami M, Onishi H, Hanagata H, et al. Efficient production of Trastuzumab Fab antibody fragments in Brevibacillus choshinensis expression system. Protein Expression and Purification, 2018,150:109-118.
doi: 10.1016/j.pep.2018.05.013
pmid: 29857036
|
|
|
[46] |
Witthoff S, Schmitz K, Niedenführ S, et al. Metabolic engineering of Corynebacterium glutamicum for methanol metabolism. Appl Environ Microbiol, 2015,81(6):2215-2225.
doi: 10.1128/AEM.03110-14
pmid: 25595770
|
|
|
[47] |
An S J, Yim S S, Jeong K J. Development of a secretion system for the production of heterologous proteins in Corynebacterium glutamicum using PorB signal peptide. Protein Expression and Purification, 2013,89(2):251-257.
doi: 10.1016/j.pep.2013.04.003
|
|
|
[48] |
Yim S S, Choi J W, Lee R J, et al. Development of a new platform for secretory production of recombinant proteins in Corynebacterium glutamicum. Biotechnol Bioeng, 2016,113(1):163-172.
doi: 10.1002/bit.25692
pmid: 26134574
|
|
|
[49] |
Matsuda Y, Itaya H, Kitahara Y, et al. Double mutation of cell wall proteins CspB and PBP1a increases secretion of the antibody Fab fragment from Corynebacterium glutamicum. Microbial cell factories, 2014,13(1):56.
doi: 10.1186/1475-2859-13-56
pmid: 24731213
|
|
|
[50] |
James M., Cregg, et al. Recent advances in the expression of foreign genes in Pichia pastoris. Nature Biotechnology, 1993.
doi: 10.1038/s41587-020-0643-8
pmid: 32839564
|
|
|
[51] |
Macauley-Patrick S, Fazenda M L, Mcneil B, et al. Heterologous protein production using the Pichia pastoris expression system. Yeast, 2005,22(4):249-270.
doi: 10.1002/yea.1208
pmid: 15704221
|
|
|
[52] |
Ferrermiralles N, Domingoespin J, Corchero J L, et al. Microbial factories for recombinant pharmaceuticals. Microbial Cell Factories, 2009,8(1):17-17.
doi: 10.1186/1475-2859-8-17
|
|
|
[53] |
Borgheresi R A, Palma M S, Ducancel F, et al. Expression and processing of recombinant sarafotoxins precursor in Pichia pastoris. Toxicon, 2001,39(8):0-1218.
|
|
|
[54] |
Anonymous. Deal watch: BMS acquires rights for IL-6 inhibitor. Nature Reviews Drug Discovery, 2010,9(1):10.
doi: 10.1038/nrd3094
pmid: 20043020
|
|
|
[55] |
Wood C R, Boss M A, Kenten J H, et al. The synthesis and in vivo assembly of functional antibodies in yeast. Nature, 1985.
doi: 10.1038/d41586-020-02537-5
pmid: 32884144
|
|
|
[56] |
Takahashi M, Kuroki Y, Ohtsubo K, et al. Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. Carbohydrate Research, 2009,344(12):1387-1390.
doi: 10.1016/j.carres.2009.04.031
pmid: 19508951
|
|
|
[57] |
Jiang Y, Li F, Zha D, et al. Purification process development of a recombinant monoclonal antibody expressed in glycoengineered Pichia pastoris. Protein Expression and Purification, 2011,76(1):0-14.
|
|
|
[58] |
Damasceno L M, Pla I, Chang H J, et al. An optimized fermentation process for high-level production of a single-chain Fv antibody fragment in Pichia pastoris. Protein Expression and Purification, 2004,37(1):0-26.
|
|
|
[59] |
Nakamura H, Oda-Ueda N, Ueda T, et al. A novel engineered interchain disulfide bond in the constant region enhances the thermostability of adalimumab Fab. Biochemical and Biophysical Research Communications, 2018,495(1):7-11.
doi: 10.1016/j.bbrc.2017.10.140
pmid: 29097200
|
|
|
[60] |
Gasser B, Prielhofer R, Marx H, et al. Pichia pastoris: protein production host and model organism for biomedical research. Future Microbiology, 2013,8(2):191-208.
doi: 10.2217/FMB.12.133
|
|
|
[61] |
Mattanovich D, Graf A, Stadlmann J, et al. Genome, secretome and glucose transport highlight unique features of the protein production host Pichia pastoris. Microbial Cell Factories, 2009,8(1):29.
doi: 10.1186/1475-2859-8-29
|
|
|
[62] |
Ridder R, Schmitz R, Legay F, et al. Generation of rabbit monoclonal antibody fragments from a combinatorial phage display library and their production in the yeast Pichia pastoris. Biotechnology, 1995,13(3):255-260.
doi: 10.1038/nbt0395-255
pmid: 9634767
|
|
|
[63] |
Ning D, Junjian X, Qing Z, et al. Production of recombinant humanized anti-HBsAg Fab fragment from Pichia pastoris by fermentation. J Biochem Mol Biol, 2005,38(3):294-299.
doi: 10.5483/bmbrep.2005.38.3.294
pmid: 15943904
|
|
|
[64] |
Gasser B, Maurer M, Gach J, et al. Engineering of Pichia pastoris for improved production of antibody fragments. Biotechnology and Bioengineering, 2006,94(2):353-361.
doi: 10.1002/bit.20851
pmid: 16570317
|
|
|
[65] |
Hou W, Meng X, Wang Y, et al. Characterization and high-yield production of non-N-glycosylated recombinant human BCMA-Fc in Pichia pastoris. Engineering in Life Sciences, 2017,17(2):96-106.
doi: 10.1002/elsc.201600039
pmid: 32624756
|
|
|
[66] |
Rakestraw J A, Sazinsky S L, Piatesi A, et al. Directed evolution of a secretory leader for the improved expression of heterologous proteins and full-length antibodies in Saccharomyces cerevisiae. Biotechnology and Bioengineering, 2009,103(6):1192-1201.
doi: 10.1002/bit.22338
pmid: 19459139
|
|
|
[67] |
Yagudin T, Klyatchko E, Zatsepin S, et al. Production of humanized F (ab') 2 fragment of rabies blocking antibodies in Pichia pastoris yeast. Applied Biochemistry and Microbiology, 2016,52(4):378-383.
doi: 10.1134/S0003683816040165
|
|
|
[68] |
Damasceno L M, Anderson K A, Ritter G, et al. Cooverexpression of chaperones for enhanced secretion of a single-chain antibody fragment in Pichia pastoris. Applied Microbiology and Biotechnology, 2007,74(2):381-389.
doi: 10.1007/s00253-006-0652-7
|
|
|
[69] |
Damasceno L M, Pla I, Chang H-J, et al. An optimized fermentation process for high-level production of a single-chain Fv antibody fragment in Pichia pastoris. Protein Expression and Purification, 2004,37(1):18-26.
doi: 10.1016/j.pep.2004.03.019
|
|
|
[70] |
Garcia-Ortega X, Ferrer P, Montesinos J L, et al. Fed-batch operational strategies for recombinant Fab production with Pichia pastoris using the constitutive GAP promoter. Biochemical Engineering Journal, 2013,79:172-181.
doi: 10.1016/j.bej.2013.07.013
|
|
|
[71] |
Jeong G M, Lee Y J, Kim Y S, et al. High-level production of Fc-fused kringle domain in Pichia pastoris. Journal of Industrial Microbiology & Biotechnology, 2014,41(6):989-996.
doi: 10.1007/s10295-014-1435-2
pmid: 24682857
|
|
|
[72] |
Arias C a D, Marques D D a V, Malpiedi L P, et al. Cultivation of Pichia pastoris carrying the scFv anti LDL (-) antibody fragment. Effect of preculture carbon source. Brazilian Journal of Microbiology, 2017,48(3):419-426.
doi: 10.1016/j.bjm.2016.11.009
pmid: 28237678
|
|
|
[73] |
Cereghino J L, Cregg J M. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. Fems Microbiology Reviews, 2000,24(1):45-66.
doi: 10.1111/j.1574-6976.2000.tb00532.x
pmid: 10640598
|
|
|
[74] |
Potgieter T I, Cukan M, Drummond J E, et al. Production of monoclonal antibodies by glycoengineered Pichia pastoris. Journal of Biotechnology, 2009,139(4):318-325.
|
|
|
[75] |
Zhang N, Liu L, Dumitru C D, et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs, 2011,3(3):289-298.
doi: 10.4161/mabs.3.3.15532
|
|
|
[76] |
Potgieter T I, Kersey S D, Mallem M R, et al. Antibody expression kinetics in glycoengineered Pichia pastoris. Biotechnology and Bioengineering, 2010,106(6):918-927.
doi: 10.1002/bit.22756
pmid: 20506148
|
|
|
[77] |
Ye J, Ly J, Watts K, et al. Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production. Biotechnology Progress, 2011,27(6):1744-1750.
doi: 10.1002/btpr.695
|
|
|
[78] |
Liu C-P, Tsai T-I, Cheng T, et al. Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation. Proceedings of the National Academy of Sciences, 2018,115(4):720-725.
|
|
|
[79] |
Aw R, Mckay P F, Shattock R J, et al. Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in Pichia pastoris. AMB Express, 2017,7(1):70-70.
doi: 10.1186/s13568-017-0372-7
pmid: 28342171
|
|
|
[80] |
Aw R, Mckay P F, Shattock R J, et al. A systematic analysis of the expression of the anti-HIV VRC01 antibody in Pichia pastoris through signal peptide optimization. Protein Expression and Purification, 2018,149:43-50.
doi: 10.1016/j.pep.2018.03.013
pmid: 29601964
|
|
|
[81] |
De Ruijter J C, Koskela E V, Frey A D. Enhancing antibody folding and secretion by tailoring the Saccharomyces cerevisiae endoplasmic reticulum. Microbial Cell Factories, 2016,15(1):87.
doi: 10.1186/s12934-016-0488-5
|
|
|
[82] |
Koskela E V, De Ruijter J C, Frey A D. Following nature’s roadmap: folding factors from plasma cells led to improvements in antibody secretion in S. cerevisiae. Biotechnology Journal, 2017,12(8):1600631.
doi: 10.1002/biot.v12.8
|
|
|
[83] |
Besada-Lombana P B, Da Silva N A. Engineering the early secretory pathway for increased protein secretion in Saccharomyces cerevisiae. Metabolic Engineering, 2019,55:142-151.
doi: 10.1016/j.ymben.2019.06.010
pmid: 31220665
|
|
|
[84] |
Van Ooyen A J, Dekker P, Huang M, et al. Heterologous protein production in the yeast Kluyveromyces lactis. Fems Yeast Research, 2006,6(3):381-392.
doi: 10.1111/j.1567-1364.2006.00049.x
pmid: 16630278
|
|
|
[85] |
Nicaud J-M, Madzak C, Van Den Broek P, et al. Protein expression and secretion in the yeast Yarrowia lipolytica. Fems Yeast Research, 2002,2(3):371-379.
doi: 10.1016/S1567-1356(02)00082-X
|
|
|
[86] |
Swennen D, Paul M-F, Vernis L, et al. Secretion of active anti-Ras single-chain Fv antibody by the yeasts Yarrowia lipolytica and Kluyveromyces lactis. Microbiology, 2002,148(1):41-50.
doi: 10.1099/00221287-148-1-41
|
|
|
[87] |
汪丽娜, 刘波, 巩新, 等. 抗 HER2 人源化单克隆抗体在乳酸克鲁维酵母中的高效表达及其产物分析. 中国生物工程杂志, 2009,29(5):44-49.
|
|
|
[87] |
Wang L N, Liu B, Gong X, et al. High expression and product analysis of anti-HER2 humanized monoclonal antibody in Kluyveromyces lactis. China Biotechnology, 2009,29(5):44-49.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|